Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (10514)	2/20/2004 12:17:25 AM
From: zeta1961	Read Replies (1) \| Respond to of 52153

Tuck...I find it interesting that Dr. Nemunaitis has also done much work with INGN's Advexin...along with CEGE and GVAX... CEGE has the largest patent estate on oncolytic viral vectors in the industry...with their cash, I don't have a good handle of why they are slower than I'd expect...perhaps too many projects going? Need more focus? Thoughts? I do agree that they and INGN are quite promising...I think I was less averse than others about INGN because because of the Human Genome Projectin which many folk from Boston were involved...one geneticist was a neighbor and his enthusiasm was infectious...it seemed to me that targeting all these genes was the natural step...delivery and sustainability of response major neg's?...Safety so far has not been an issue... Regards, Zeta